Johnson & Johnson Profit Margin 2010-2024 | JNJ

Current and historical gross margin, operating margin and net profit margin for Johnson & Johnson (JNJ) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Johnson & Johnson net profit margin as of December 31, 2024 is 18.2%.
Johnson & Johnson Annual Profit Margins
Johnson & Johnson Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $399.649B $88.821B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $783.103B 63.53
AbbVie (ABBV) United States $370.636B 20.70
Novo Nordisk (NVO) Denmark $311.614B 21.11
Roche Holding AG (RHHBY) Switzerland $262.452B 0.00
Novartis AG (NVS) Switzerland $227.865B 14.27
Merck (MRK) United States $226.737B 11.75
Pfizer (PFE) United States $143.715B 8.15
Sanofi (SNY) $140.749B 13.33
Bayer (BAYRY) Germany $23.657B 4.39
Innoviva (INVA) United States $1.136B 10.48